Nervous system - Systema nervosum | Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors

excerpt from an edition:

A T L A S - Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors /Second supplemented edition/ - DOI: 10.5281/zenodo.13777292 | ISBN: 978-619-91534-6-8

--------------

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (p.10 form the ATLAS) of transcriptome cell lines inherent in tumors in the Nervous system (a. & b.), it is concluded that:

- some of the main potential medicines:

(2S,3S)-2-hydroxy-4-methoxy-1-methyl-6-oxo-3-(((2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,2,3,6-tetrahydropyridine-3-carboxamide and .../carboxylic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (2S,3S)-2,3-dihydroxy-4-methoxy-1-methyl-6-oxo-1,2,3,6-tetrahydropyridine-3-carboxamide and .../carboxylic acid ,

(R)-2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)butanamide and .../butanoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-2-methylbutanamide and .../butanoic acid ,

(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)but-3-enamide and .../enoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-3-methylbut-3-enamide and .../enoic acid ,

(Z)-2-((2S,3R,4S,6R)-2,3-dihydroxy-4-methoxy-6-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexylidene)acetamide and .../acetic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (E)-2-((2S,3R,4S,6R)-2,3,6-trihydroxy-4-methoxycyclohexylidene)acetamide and .../acetic acid ,

(E)-2-carbamoyl-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-yl 4-hydroxy-3,5-dimethoxybenzoate and (E)-2-(((4-hydroxy-3,5-dimethoxybenzoyl)oxy)methyl)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-enoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (E)-2-carbamoyl-4-hydroxybut-2-en-1-yl 4-hydroxy-3,5-dimethoxybenzoate and (E)-4-hydroxy-2-(((4-hydroxy-3,5-dimethoxybenzoyl)oxy)methyl)but-2-enoic acid ,

the rest ACCF can be found in the file and the ATLAS ;

- certain medicines for duplication of treatment and/or replacement for medical reasons:

(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide and .../acetic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-2-phenylacetamide and .../acetic acid ,

(2R,3R,4S,5R,6R)-2-(((Z)-4-amino-2-methyl-4-oxobut-2-en-1-yl)oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl acetate and (Z)-4-(((2R,3R,4S,5R,6R)-4-acetoxy-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-methylbut-2-enoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (Z)-4-hydroxy-3-methylbut-2-enamide and .../enoic acid ,

(Z)-2-(hydroxymethyl)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-enamide and .../enoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (Z)-4-hydroxy-2-(hydroxymethyl)but-2-enamide and .../enoic acid ,

the rest ACCF can be found in the file and the ATLAS.

-------

Important! Do not forget to comply with the current clinical control.

The idea timeline: anti-cancer.eu